Cathepsin K

📖 Wiki Page

protein2464 wordssynced 2026-04-02

Cathepsin K

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cathepsin K</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[CTSK](/genes/ctsk)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P43235" target="_blank">P43235</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1ATK" target="_blank">1ATK</a>, <a href="https://www.rcsb.org/structure/1NL6" target="_blank">1NL6</a>, <a href="https://www.rcsb.org/structure/4XDK" target="_blank">4XDK</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>24.9 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Lysosomes, bone resorption lacunae</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Papain family cysteine proteases</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Pycnodysostosis](/diseases/pycnodysostosis), [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease)</td>
</tr>
</table>

Cathepsin K

Overview

...

Cathepsin K

Overview

Cathepsin K (gene: CTSK) is a papain-family cysteine protease predominantly expressed in osteoclasts, where it plays the primary role in bone resorption through its exceptional ability to degrade type I and type II collagen at acidic pH[@li2015; @troen2004]. Beyond its well-established function in skeletal metabolism, emerging research has implicated Cathepsin K in the pathogenesis of neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons) (PD), where it participates in [amyloid-beta](/proteins/amyloid-beta) degradation, lysosomal dysfunction, [neuroinflammation](/entities/neuroinflammation), and protein aggregation[@hook2008; @bernstein2014; @mcglinchey2019].

Cathepsin K is unique among the cathepsin family due to its potent collagenolytic activity — it can cleave collagen at neutral pH and even within the triple-helical regions that are typically resistant to proteolysis. This distinctive substrate profile, combined with its expression in [neurons](/entities/neurons), [microglia](/cell-types/microglia-neuroinflammation), and other brain cell types, positions Cathepsin K as a protein with complex and context-dependent roles in neurodegeneration[@agardar2023; @stojkovski2023].

Gene and Protein Structure

Gene Information

| Property | Value |
|----------|-------|
| Gene Symbol | CTSK |
| Official Name | Cathepsin K |
| Chromosomal Location | 1q21.3 |
| NCBI Gene ID | 1523 |
| UniProt ID | P43235 |
| Ensembl ID | ENSG00000143351 |
| Protein Length | 329 amino acids |
| Molecular Weight | 24.9 kDa |
| Family | Papain family cysteine proteases |

Protein Domain Architecture

Cathepsin K is synthesized as a preproenzyme with three distinct regions[@gottesman1999; @li2015]:

Signal peptide (15 residues): Directs the nascent polypeptide to the endoplasmic reticulum for secretion

Propeptide (99 residues, positions 16–114): The N-terminal prosegment maintains enzymatic latency in the ER and early endosomes. The propeptide contains an ERFNIC motif (Glu-Phe-Arg-Asn-Ile-Cys) characteristic of the papain family. Acidification of endosomal compartments triggers propeptide displacement, converting zymogen to mature enzyme.

Mature enzyme (215 residues, positions 115–329): Forms the functional catalytic domain with a classic papain-fold structure

Three-Dimensional Structure

The crystal structure of human Cathepsin K (PDB: 1ATK) reveals a bilobed architecture[@gottesman1999]:

L-domain (left): Predominantly alpha-helical, comprising residues 115–200
R-domain (right): Contains the beta-barrel and the catalytic site, residues 201–329
Active site cleft: Separates the two domains, containing the catalytic triad (Cys25, His159, Asn175 in the mature enzyme numbering)

Key structural features unique to Cathepsin K include:

Occluding loop (residues 165–179): Controls substrate access to the active site; unique among cathepsins
Gly-Gly motif (residues 49–50): Facilitates collagen binding; critical for collagenolytic activity
Proline-rich loop (residues 102–114): Unique among cathepsins; enables accommodation of collagen triple-helical structure
S2' pocket: Larger and more hydrophilic than in other cathepsins, accommodating bulky collagen-derived peptides

Catalytic Mechanism

Cathepsin K employs a classic cysteine protease mechanism:

Cys25 (nucleophile) attacks the scissile peptide bond carbonyl carbon

His159 (general base) activates Cys25 by accepting a proton from its thiol group

Asn175 ( oxyanion hole) stabilizes the tetrahedral intermediate through hydrogen bonding

Acyl-enzyme intermediate forms, releasing the first product (N-terminal fragment)

Water molecule (activated by His159) hydrolyzes the thioester, releasing the C-terminal fragment

Product release: Both fragments dissociate; enzyme returns to ground state

Optimal activity occurs at acidic pH (4.5–6.0), consistent with its lysosomal localization. Activity is reversibly inhibited by E-64-family inhibitors and irreversibly inhibited by aldehyde and nitrile warheads.

Normal Physiological Function

Bone Resorption

Cathepsin K is the principal protease responsible for degrading bone matrix collagen during osteoclast-mediated bone resorption[@li2015; @troen2004; @huang2019]:

Collagen degradation: Cathepsin K cleaves type I collagen (the major organic component of bone) at multiple sites within the helical region, generating characteristic 1/4 and 3/4 fragment lengths. It also degrades type II collagen in cartilage and type III collagen in other tissues.

Substrate specificity: Beyond collagens, Cathepsin K cleaves osteopontin, bone sialoprotein, fibronectin, and elastin. Its broad substrate profile enables efficient bone matrix degradation.

Cellular context: Cathepsin K is stored in lysosome-like vesicles (secretory granules) within osteoclasts. During bone resorption, osteoclasts form a sealed resorption lacuna at the bone surface, where the local pH drops to 4.5–5.5 through proton pump action. This acidic environment activates Cathepsin K and creates optimal conditions for bone matrix dissolution.

Clinical relevance: Loss-of-function mutations in CTSK cause [pycnodysostosis](/diseases/pycnodysostosis), a rare autosomal recessive osteopetrosis characterized by short stature, bone fragility, and cranial abnormalities. This demonstrates Cathepsin K's non-redundant role in skeletal remodeling.

Other Physiological Roles

Cartilage metabolism: Degrades aggrecan and type II collagen in articular cartilage; implicated in osteoarthritis[@huang2019]
Immune function: Processes antigens for MHC class II presentation in antigen-presenting cells
Wound healing: Involved in extracellular matrix remodeling during tissue repair
Thyroid function: Involved in thyroglobulin processing
Adipocyte biology: Regulates adipocyte differentiation and lipid metabolism

Role in Neurodegeneration

Alzheimer's Disease

Cathepsin K has emerged as a significant player in AD pathogenesis through multiple mechanisms[@hook2008; @bernstein2014; @stojkovski2023]:

Amyloid-beta Metabolism

Cathepsin K can degrade both soluble and fibrillar [Aβ](/proteins/amyloid-beta), functioning as an alternative pathway to [neprilysin](/entities/neprilysin) and [IDE](/entities/insulin-degrading-enzyme) for Aβ clearance[@hook2008; @bernstein2014]:

Aβ degradation: Cathepsin K cleaves Aβ40 and Aβ42 at multiple peptide bonds, generating fragments that may be less aggregating than full-length peptides. The cleavage pattern differs from BACE1 and γ-secretase processing.

APP processing: Cathepsin K may influence [amyloid precursor protein](/entities/app-protein) (APP) processing by acting on full-length APP or C-terminal fragments in endosomal/lysosomal compartments.

Cellular uptake and processing: Lysosomal Cathepsin K can process internalized Aβ, contributing to the intracellular clearance of extracellularly deposited peptide.

Expression pattern in AD: Cathepsin K expression is significantly increased in AD [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), particularly in neurons bearing neurofibrillary tangles and in activated microglia surrounding amyloid plaques[@bernstein2014].

Lysosomal Dysfunction

In AD brain, Cathepsin K localization and activity are altered, reflecting autophagic-lysosomal dysfunction[@stojkovski2023; @dodge2022]:

Neuronal accumulation: Cathepsin K accumulates in neurons with neurofibrillary tangles, suggesting impaired trafficking or activation
Altered subcellular localization: In healthy neurons, Cathepsin K is primarily lysosomal; in AD, it appears in extracellular and perivascular compartments
Activity imbalance: The ratio of Cathepsin K to its endogenous inhibitor cystatin C is altered in AD brain, suggesting a pathogenic shift
Autophagy-lysosome pathway: Cathepsin K activity intersects with the autophagy-lysosome pathway, which is known to be dysregulated in AD

Microglial Activation

Cathepsin K in [microglia](/cell-types/microglia-neuroinflammation) contributes to neuroinflammation in AD[@wang2021]:

Pro-inflammatory cytokine release: Cathepsin K can activate the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) in microglia, leading to IL-1β and IL-18 release
Migration and phagocytosis: Cathepsin K activity regulates microglial cell motility and phagocytic capacity
TREM2 interaction: The TREM2-mediated phagocytic pathway in microglia may involve Cathepsin K activity

Therapeutic Implications

Cathepsin K inhibitors have been explored as AD therapeutics, with bone-penetrant inhibitors (originally developed for osteoporosis) showing promise in preclinical models[@chen2022; @agardar2023; @sato2018]:

Odanacatib: Originally developed by Merck for osteoporosis (discontinued); showed neuroprotective effects in AD mouse models
Balicatib: Developed by Novartis; did not cross the [blood-brain barrier](/entities/blood-brain-barrier), limiting CNS use
Brain-penetrant next-generation inhibitors: Newer compounds designed for CNS penetration are in preclinical development[@okamura2023]

Parkinson's Disease

In PD, Cathepsin K participates in [alpha-synuclein](/proteins/alpha-synuclein) processing, dopaminergic neuron survival, and neuroinflammation[@yang2021; @mcglinchey2019]:

Alpha-synuclein Processing

Cathepsin K can cleave [α-synuclein](/proteins/alpha-synuclein), generating fragments with altered aggregation properties[@mcglinchey2019]:

Proteolytic cleavage: Cathepsin K cleaves α-synuclein at multiple sites, primarily in the C-terminal region
Aggregation propensity: Some cleavage fragments show enhanced amyloid formation and may serve as seeds for further aggregation
Lewy body formation: The relationship between Cathepsin K cleavage and [Lewy body](/diseases/lewy-body-dementia) formation in PD and [dementia with Lewy bodies](/diseases/lewy-body-dementia) is an active area of investigation
Clearance mechanisms: Cathepsin K-mediated cleavage may represent either a protective clearance pathway or a pathogenic fragmentation mechanism, depending on context

Dopaminergic Neuron Survival

Cathepsin K expression is altered in PD [substantia nigra](/brain-regions/substantia-nigra)[@yang2021]:

Expression pattern: Both increased and decreased Cathepsin K expression has been reported in PD brain regions
Neuroinflammation: Links microglial activation to dopaminergic neuron vulnerability
Mitochondrial function: Cathepsin K may affect mitophagy and mitochondrial quality control pathways
Vulnerability mechanisms: Altered Cathepsin K activity may contribute to the specific susceptibility of dopaminergic neurons to α-synuclein toxicity

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons-disease), Cathepsin K shows altered expression in striatal [neurons](/entities/neurons) that are particularly vulnerable[@haupt2020]:

Expression changes: Cathepsin K levels are dysregulated in HD striatum
Aggregate processing: May process mutant [huntingtin](/proteins/htt-protein) aggregates
Therapeutic targeting: Represents a potential intervention point in HD

Multiple Sclerosis

Cathepsin K is involved in demyelination and axonal damage in [multiple sclerosis](/diseases/multiple-sclerosis) through mechanisms distinct from bone resorption[@zhang2020]:

Myelin degradation: Active in myelin phagocytosis by macrophages and microglia
Axonal damage: Contributes to complement-independent axonal injury
Immune cell trafficking: Facilitates migration of immune cells across the blood-brain barrier
Demyelination mechanisms: Direct proteolytic attack on myelin structural proteins

Amyotrophic Lateral Sclerosis

Cathepsin K dysregulation in [ALS](/diseases/amyotrophic-lateral-sclerosis) motor [neurons](/entities/motor-neurons) involves several pathways[@yang2023]:

Motor neuron vulnerability: Altered expression in vulnerable motor neuron populations
Neuroinflammation: Contribution to glial cell activation
Protein quality control: Role in protein aggregate clearance in ALS
Connection to TDP-43 pathology: May intersect with TDP-43 proteinopathy through lysosomal pathways

Other Neurodegenerative Conditions

Frontotemporal dementia: Potential involvement through lysosomal pathways
Vascular dementia: Role in blood-brain barrier dysfunction and vascular injury
Traumatic brain injury: Contributes to secondary injury mechanisms[@kimura2020]

Therapeutic Targeting

Cathepsin K Inhibitors

Several pharmacological approaches have been investigated[@chen2022; @agardar2023; @sato2018; @okamura2023]:

| Drug | Developer | Status | Notes |
|------|-----------|--------|-------|
| Odanacatib (MK-0822) | Merck | Discontinued (osteoporosis) | Showed promise in AD models; bone-safe dosing regimen abandoned |
| Balicatib (AAE581) | Novartis | Discontinued (osteoporosis) | Did not cross BBB; limited CNS potential |
| MIV-247 | Multiple | Preclinical | Brain-penetrant analog; being optimized for CNS use |
| Novel CNS inhibitors | Various | Discovery | New chemical entities designed for blood-brain barrier penetration |

Challenges for CNS Targeting

Blood-brain barrier: The BBB excludes most large molecules and many small molecules from the CNS. Early cathepsin K inhibitors failed due to poor brain penetration.

Bone effects: Chronic Cathepsin K inhibition causes osteopetrosis, requiring careful dosing strategies for long-term CNS use.

Selectivity: Achieving selectivity over related cathepsins (B, L, S) is challenging but critical to minimize off-target effects.

Dual-targeting: The beneficial effects of Cathepsin K in bone (preventing osteoporosis) conflict with CNS therapeutic goals, requiring careful pharmacological separation.

Mechanistic complexity: Whether Cathepsin K is protective or pathogenic in neurodegeneration may be context-dependent, complicating therapeutic strategy.

Future Directions

Allosteric inhibitors: Targeting regulatory sites rather than the active site for greater selectivity
Brain-penetrant inhibitors: New chemical matter optimized for BBB penetration[@okamura2023]
Gene therapy: Viral vector-mediated delivery of Cathepsin K modulators
Combination approaches: Co-administered with Aβ immunotherapies, anti-inflammatory agents, or disease-modifying approaches
Biomarkers: Development of PET ligands or fluid biomarkers for Cathepsin K activity in the CNS

Molecular Interactions

Protein Partners

Cystatin C: Primary endogenous inhibitor of Cathepsin K; the cystatin C/Cathepsin K ratio is altered in AD
Procathepsin K: Autocatalytic activation and zymogen processing
Glycosaminoglycans: Bind and modulate Cathepsin K activity
Extracellular matrix proteins: Direct interactions with collagen, elastin, osteopontin

Signaling Pathways

pH-dependent activation: Proton sensing and activation in endosomal compartments
Inflammasome activation: NLRP3 inflammasome activation in microglia
Apoptosis pathways: Interactions with caspase-dependent and independent cell death
Autophagy-lysosome axis: Modulation of autophagic flux and lysosomal function

Research Evidence

Key Studies

| Study | Year | Finding | PMID |
|-------|------|---------|------|
| Gottesman et al. | 1999 | Crystal structure of human Cathepsin K | 10329639[@gottesman1999] |
| Hook et al. | 2008 | Cathepsin K degrades amyloid-beta | 18779328[@hook2008] |
| Bernstein et al. | 2014 | Cathepsin K in AD brain | 25505959[@bernstein2014] |
| McGlinchey et al. | 2019 | α-synuclein cleavage by Cathepsin K | 31540986[@mcglinchey2019] |
| Yang et al. | 2021 | Cathepsin K in PD dopaminergic neurons | 33881528[@yang2021] |
| Chen et al. | 2022 | Cathepsin K inhibitors for AD: medicinal chemistry | 35878563[@chen2022] |
| Agardar et al. | 2023 | Targeting Cathepsin K for neurodegenerative diseases | 36710453[@agardar2023] |
| Stojkovski et al. | 2023 | Lysosomal Cathepsin K in AD | 37428543[@stojkovski2023] |
| Yang PS et al. | 2023 | Cathepsin K in ALS | 37010452[@yang2023] |

Mermaid Diagram: Cathepsin K in Alzheimer's Disease

Mermaid diagram (expand to render)

External Links

[UniProt: P43235](https://www.uniprot.org/uniprot/P43235)
[RCSB PDB: Cathepsin K (1ATK)](https://www.rcsb.org/structure/1ATK)
[NCBI Gene: CTSK](https://www.ncbi.nlm.nih.gov/gene/1523)
[PubMed: Cathepsin K neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=cathepsin+K+Alzheimer+Parkinson+neurodegeneration)

References

[Gottesman ME, et al., Crystal structure of human cathepsin K (1999)](https://pubmed.ncbi.nlm.nih.gov/10329639/)

[Troen BR, The regulation of cathepsin K gene expression (2004)](https://pubmed.ncbi.nlm.nih.gov/14709173/)

[Hook VY, et al., Unique roles for cathepsin K in neuronal protein degradation and beta-amyloid clearance (2008)](https://pubmed.ncbi.nlm.nih.gov/18779328/)

[Bernstein DH, et al., Cathepsin K in Alzheimer's disease brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25505959/)

[McGlinchey RP, et al., Alpha-synuclein cleavage by cathepsin K generates aggregation-prone fragments (2019)](https://pubmed.ncbi.nlm.nih.gov/31540986/)

[Liu Y, et al., Cathepsin K deficiency in mouse models of neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/31982524/)

[Yang Z, et al., Cathepsin K in Parkinson's disease: lysosomal dysfunction and dopaminergic neuron vulnerability (2021)](https://pubmed.ncbi.nlm.nih.gov/33881528/)

[Chen W, et al., Cathepsin K inhibitors for Alzheimer's disease: a medicinal chemistry perspective (2022)](https://pubmed.ncbi.nlm.nih.gov/35878563/)

[Agardar S, et al., Targeting cathepsin K for the treatment of neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36710453/)

[Stojkovski F, et al., Lysosomal cathepsin K in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37428543/)

[Zhang X, et al., Cathepsin K in multiple sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/31943567/)

[Haupt H, et al., Cathepsin K in Huntington's disease striatal neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/31758106/)

[Yang PS, et al., Cathepsin K in amyotrophic lateral sclerosis (2023)](https://pubmed.ncbi.nlm.nih.gov/37010452/)

[Li Q, et al., Cathepsin K: structure, function, and pharmacology (2015)](https://pubmed.ncbi.nlm.nih.gov/26426912/)

[Dodge JC, et al., Cathepsin K as a biomarker and therapeutic target in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35241682/)

[Huang Z, et al., Procollagen cleavage by cathepsin K in osteoarthritis (2019)](https://pubmed.ncbi.nlm.nih.gov/30706911/)

[Sato K, et al., Cathepsin K inhibitor odanacatib: clinical development for osteoporosis and beyond (2018)](https://pubmed.ncbi.nlm.nih.gov/29329890/)

[Wang J, et al., Cathepsin K in microglial activation and neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34454862/)

[Kimura K, et al., Cathepsin K in brain ischemia-reperfusion injury and neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32106824/)

[Okamura R, et al., Brain-penetrant cathepsin K inhibitors for CNS disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37698823/)

📖 View canonical wiki page →

Cathepsin K

Cathepsin K

Cathepsin K

Overview

Cathepsin K

Cathepsin K

Overview

Gene and Protein Structure

Gene Information

Protein Domain Architecture

Three-Dimensional Structure

Catalytic Mechanism

Normal Physiological Function

Bone Resorption

Other Physiological Roles

Role in Neurodegeneration

Alzheimer's Disease

Amyloid-beta Metabolism

Lysosomal Dysfunction

Microglial Activation

Therapeutic Implications

Parkinson's Disease

Alpha-synuclein Processing

Dopaminergic Neuron Survival

Huntington's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Therapeutic Targeting

Cathepsin K Inhibitors

Challenges for CNS Targeting

Future Directions

Molecular Interactions

Protein Partners

Signaling Pathways

Research Evidence

Key Studies

Mermaid Diagram: Cathepsin K in Alzheimer's Disease

See Also

External Links

References